ALEXANDRIA, Va., Aug. 6 -- United States Patent no. 12,377,106, issued on Aug. 5, was assigned to NURIX THERAPEUTICS INC. (San Francisco).
"Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading BTK" was invented by Robert J. Brown (San Francisco) and Arthur T. Sands (San Francisco).
According to the abstract* released by the U.S. Patent & Trademark Office: "This disclosure relates to BTK inhibitor compounds for treating or preventing cancer by daily oral dosing in human subjects in need thereof. The description also provides BTK inhibitor compounds for degrading BTK in vivo by daily oral dosing in human subjects in need thereof."
The patent was filed on Oct. 25, 2022, under Application No. 18/049,...